ArticleIn vitro cellular & developmental biology. Animal2026
Network pharmacology analysis and experimental validation of modified Taohong Siwu decoction against atherosclerosis.
Article in In vitro cellular & developmental biology. Animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The modified Taohong Siwu decoction (MTHSWD), a traditional prescription, demonstrates notable efficacy in treating cardiovascular diseases. However, its potential mechanisms in addressing atherosclerosis (AS) require further exploration. Investigating the underlying mechanisms of MTHSWD in treating AS is imperative. AS mouse models received MTHSWD treatment, with vascular pathology and fibrosis assessed through histopathological staining. Network pharmacology identified bioactive components and potential targets, followed by molecular docking verification of key compound-target interactions. Biochemical validation included Western blot analysis. MTHSWD significantly ameliorated vascular structural abnormalities and fibrosis in AS models. Network pharmacology analysis revealed 133 active components targeting 295 proteins, intersecting with 3309 AS-related genes to form 191 overlapping targets. Twenty-two components (e.g., quercetin) demonstrated multi-target activity (≥ 15 targets). PPI network topology identified 32 hub targets including AKT1, MAPK1/8/14. Functional analysis showed that apoptosis, MAPK signaling, and lipid metabolism pathways were significantly enriched. The pathway-target network highlighted AKT1 and MAPK family members as central regulators. Molecular docking confirmed strong interactions (binding energy < -9.0 kcal/mol) between AKT1-stigmasterol/anhydroicaritin, MAPK1-emodin, and MAPK8/14-β-carotene. Experimental validation demonstrated MTHSWD's regulation of AKT1, MAPK1/14, cleaved-caspase-3, and Bcl-2 expression, enhancing endothelial viability while suppressing apoptosis. This integrated approach reveals that MTHSWD exerts anti-AS effects through multi-target modulation of PI3K/AKT and MAPK signaling pathways, promoting endothelial survival and attenuating apoptotic processes, ultimately alleviating AS-related vascular pathology.
Indexed as
Identifiers
41832335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.